Having trouble viewing this email? View the online version.
ISSM logo

Latest News from the ISSM - March 20, 2015 Member Login
FDA Calls for Testosterone Label Changes Amidst Questions about Cardiovascular Risk

Testosterone products approved by the U.S. Food and Drug Administration (FDA) will now need to clarify approved uses and provide information on possible cardiovascular risks.

The agency announced these changes on March 3, 2015.

The labeling changes are prompted by two concerns.

First, the FDA has approved testosterone therapy only for treatment of hypogonadism - low testosterone due to medical conditions.

Testosterone has not been approved for age-related testosterone declines. The FDA says more research is needed in this area. New labeling should make this clear. 

Second, manufacturers of testosterone must now conduct further research on potential cardiovascular risks associated with testosterone therapy and note these possible risks on package labels.

This change is the result of recent research suggesting an increased risk of heart attack and stroke in certain patients.

However, such risks are a matter of debate among professionals and the research methods of these studies have been questioned.

In January, members of the Androgen Study Group published a review of dozens of studies on testosterone and cardiovascular risk.  The report appeared in Mayo Clinic Proceedings.

The members noted that four studies found increased risk.  But many more showed "a beneficial effect of normal [testosterone] levels on [cardiovascular] risks and mortality."

The authors added, "In summary, there is no convincing evidence of increased [cardiovascular] risks with [testosterone] therapy. On the contrary, there appears to be a strong beneficial relationship between normal [testosterone] and [cardiovascular] health that has not yet been widely appreciated."

For more information on both the FDA rules and the literature review, please click here

Sexual Medicine - Discounted Publishing Rate Still Available for ISSM Members

For a limited time, ISSM members may publish in Sexual Medicine, the ISSM's open access journal, for $100.

This subsidy applies to 20 papers authored by ISSM members that are accepted for publication in Sexual Medicine. For eligible papers, ISSM members pay a special discounted rate of $100 (regularly $500).

This offer is available to ISSM members only. Please click here to submit your manuscript. More information about publishing in Sexual Medicine may be found here.

Further details about this program are available here.

You are receiving this newsletter because you are subscribed to our mailing list.
If you would rather not receive emails like this in the future you can unsubscribe.

ISSM | International Society for Sexual Medicine
P.O. Box 94 | 1520 AB Wormerveer | The Netherlands